Home > Insider Trading > Filing (0000899243-19-029783)

Filing Details

Accession Number:: 0000899243-19-029783
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-20 17:11:31
Reporting Period:: 2019-12-18

Accepted Time:: 2019-12-20 17:11:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492422	Apellis Pharmaceuticals Inc.	APLS	Pharmaceutical Preparations (2834)	271537290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1721108	Sinclair A. Dunlop	C/O Apellis Pharmaceuticals, Inc 6400 Westwind Way, Suite A Crestwood KY 40014		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-12-18	25,890	$28.55	374,791	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-12-19	54,110	$28.99	320,681	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-12-19	31,000	$29.51	249,728	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2019-12-20	25,000	$29.53	224,728	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The reported transaction involved a sale of shares held by Epidarex Capital I, LP ("Epidarex"). The price reported in Column 4 is a weighted average price. On December 18, 2019, the shares were sold in multiple transactions at prices ranging from $28.17 to $29.11. On December 19, 2019, the shares were sold in multiple transactions at prices ranging from $28.77 to $29.26. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
The reported transaction involved a sale of shares held by MASA Life Science Ventures, LP ("MASA"). The price reported in Column 4 is a weighted average price. On December 19, 2019, the shares were sold in multiple transactions at prices ranging from $29.30 to $29.80. On December 20, 2019, the shares were sold in multiple transactions at prices ranging from $29.25 to $29.76.
The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.